Lancet
-
Randomized Controlled Trial Multicenter Study
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. ⋯ Alliance for Better Bone Health (Warner Chilcott and Sanofi).
-
Randomized Controlled Trial Multicenter Study
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
A substantial proportion of patients with type 2 diabetes are elderly (≥65 years) but this group has been largely excluded from clinical studies of glucose-lowering drugs. We aimed to assess the effectiveness of linagliptin, a dipeptidyl peptidase-4 inhibitor, in elderly patients with type 2 diabetes. ⋯ Boehringer Ingelheim.